Kyowa Kirin acquires Asian rights to Reata's lead drug
Reata Pharmaceuticals has licensed its lead development project bardoxolone methyl (RTA 402) to Kyowa Hakko Kirin for development and commercialisation in Japan and other Asian markets.
Reata Pharmaceuticals has licensed its lead development project bardoxolone methyl (RTA 402) to Kyowa Hakko Kirin for development and commercialisation in Japan and other Asian markets.